Europe Scleroderma Therapeutics Market – Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Publish Reports
  • Europe
  • 350 Pages
  • No of Tables: 21
  • No of Figures: 109

Europe Scleroderma Therapeutics Market By Type (Localized Scleroderma, Systemic Scleroderma), Treatment Type (Drug Treatment, Surgical Treatment, Therapy), End User (Hospital, Specialty Clinics, Homecare Settings, Others), Country (U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Belgium, Turkey, Russia, Rest of Europe) Industry Trends and Forecast to 2026 – Industry Trends and Forecast to 2026

The scleroderma is an auto-immune disease of unknown etiology and is characterized by fibrosis and microvascular injury in affected organs. In this disease, Raynaud’s phenomenon is an initial symptom and shows puffiness of fingers. There are two types of scleroderma - localized scleroderma and limited cutaneous systemic sclerosis. Localized sclerosis shows plaques of fibrotic skin and subcutaneous tissue which further occurs as linear fibrotic bands on extremities such as skin and deeper tissue. Hence, it has two types in localized scleroderma and they are morphea and linear scleroderma. As per the studies carried out by researchers, it has been found that the disease occurs due to the changes in certain parameter in environment or changes in certain gene in human. The symptoms involves in this disease is abnormalities on the skin, painful joints, morning stiffness, fatigue, and/or weight loss and many others.

There is no drug or treatment available to treat scleroderma but there are certain drugs available which can be used in treating the disease associated to scleroderma such as kidney disease, Heartburn (acid reflux), Raynaud's phenomenon and others. Some of them are aspirin, naproxen, ibuprofen and many others.

Europe scleroderma therapeutics market is projected to register a healthy CAGR in the forecast period of 2019 to 2026.

Segmentation: Europe Scleroderma Therapeutics Market

Europe Scleroderma Therapeutics Market is segmented into three notable segments such as type, treatment type, end user.

  • On the basis of type, the market is segmented into localized scleroderma and systemic scleroderma
    • In March 2019, Sanofi received FDA (Food and Drug Administration) approved Dupixent (dupilumab) which is useful for moderate-to-severe atopic dermatitis in adolescents. It is used for treating the skin related issues as it clears the skin and reduced itching in adolescents. With this approval the company has increased its portfolio and also increased its business bry provides product everywhere around the world.
  • On the basis of treatment type, the market is segmented into drug treatment, surgery treatment and therapy
    • In February 2018, Novartis's Sandoz division received U.S. approval for a larger dosage of its product called Glatopa drug which is useful for treatment of multiple sclerosis patients, approval of product reinforces company’s leadership in market.
  • On the basis of end user, the Europe scleroderma therapeutics market is segmented into hospital, speciality clinics, homecare settings and others
    •  In May 2017, F. Hoffmann-La Roche Ltd received U.S. Food and Drug Administration (FDA) for its product Actemra/RoActemra (tocilizumab) subcutaneous injection that is useful for treatment of GCA. GCA chronic and severe autoimmune condition and Actemra/RoActemra (tocilizumab) is the first FDA approved treatment for GCA in adults. It is the 6th approval after its first U.S. launch in 2010

Competitive Analysis: Europe Scleroderma Therapeutics Market

Some of the prominent participants operating in this market are Argentis Pharmaceuticals, LLC., F. Hoffmann-La Roche Ltd, AbbVie Inc., Pfizer Inc., Sanofi, ALLERGAN, viDA Therapeutics Inc., Novartis AG, Active Biotech AB., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Johnson & Johnson Services, Inc., AstraZeneca, Daval International Limited and among others.

Recent Developments:

  • In September 2017, Roche received European approval for Actemra /RoActemra in giant cell arteritis. It is the first therapy which is used in treatment of giant cell arteritis (GCA) in Europe. With this approval company has strengthen their business in market by increasing their products which is helpful in treating diseases.
  • In April 2016, Allergan acquired Topokin Therapeutics, a topical dermatology company, and adding non-invasive reduction development program. Main highlight of company is TAT4 gel, is a therapy that increases subcutaneous fat of hand and face.
  • In January 2014, Actelion Ltd launched Opsumit and is now available in Germany. Opsumit (macitentan) is long term treatment of pulmonary arterial hypertension (PAH) and with this company increased its product portfolio. The product has also approved by the EU Commission for its product.

Research Methodology: Europe Scleroderma Therapeutics Market

Primary Respondents:

Key Opinion Leaders (KOL’s): Manufacturer, Healthcare Professionals, Doctors, Nurses, Medical practitioners.

Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and, National Sales Managers.

TABLE OF CONTENTS EUROPE SCLERODERMA THERAPEUTICS MARKET

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 OVERVIEW OF EUROPE SCLERODERMA THERAPEUTICS MARKET 1.4 CURRENCY AND PRICING 1.5 LIMITATIONS 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED 2.2 EUROPE SCLERODERMA THERAPEUTICS MARKET : GEOGRAPHICAL SCOPE 2.3 YEARS CONSIDERED FOR THE STUDY 2.4 CURRENCY AND PRICING 2.5 DBMR TRIPOD DATA VALIDATION MODEL 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.7 DBMR MARKET POSITION GRID 2.8 TIME LINE 2.9 MULTIVARIATE MODELLING 2.10 SECONDARY SOURCES 2.11 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.1.1 RISING CASES OF SCLERODERMA 3.1.2 INCREASING ACCESS TO MEDICAL INSURANCE IN THE U.S. 3.1.3 INCREASING MERGER AND ACQUISITIONS

3.2 RESTRAINTS

3.2.1 LACK OF CURATIVE TREATMENT 3.2.2 STRINGENT REGULATIONS 3.2.3 COUNTERFEIT PRODUCTS

3.3 OPPORTUNITY

3.3.1 UNMET PATIENT NEEDS IN SYSTEMIC SCLEROSIS

3.4 CHALLENGE

3.4.1 SIDE EFFECTS OF DRUGS

4 EXECUTIVE SUMMARY 5 PREMIUM INSIGHTS 6 PIPELINE PRODUCTS 7 EPIDEMIOLOGY

7.1 HISTORY OF SCLERODERMA: 7.2 RECENT INCIDENCE AND PREVALENCE: 7.3 CAUSE OF SCLERODERMA: 7.4 SYMPTOMS OF SCLERODERMA: 7.5 MANAGING SCLERODERMA:

8 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY TYPE

8.1 OVERVIEW 8.2 SYSTEMIC SCLERODERMA

8.2.1 LIMITED CUTANEOUS SYSTEMIC SCLEROSIS OR CREST SYNDROME 8.2.2 DIFFUSE SYSTEMIC SCLEROSIS

8.3 LOCALIZED SCLERODERMA

8.3.1 MORPHEA 8.3.2 LINEAR SCLERODERMA

9 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE

9.1 OVERVIEW 9.2 DRUG TREATMENT

9.2.1 DRUG TREATMENT, BY TYPE

9.2.1.1 ANTI-INFLAMMATORY DRUGS 9.2.1.2 IMMUNOSUPPRESSANTS 9.2.1.3 CORTICOSTEROIDS 9.2.1.4 PROTON PUMP INHIBITORS 9.2.1.5 CALCIUM CHANNEL BLOCKERS 9.2.1.6 ACE INHIBITORS 9.2.1.7 H2 BLOCKERS 9.2.1.8 PDE5 INHIBITORS 9.2.1.9 PROSTACYCLIN ANALOGUES 9.2.1.10 ENDOTHELIN RECEPTOR ANTAGONISTS 9.2.1.11 CHELATING AGENTS (EDATHAMIL DISODIUM) 9.2.1.12 OTHERS

9.2.2 DRUG TREATMENT, BY DISTRIBUTION CHANNEL

9.2.2.1 HOSPITAL PHARMACY 9.2.2.2 RETAIL PHARMACY 9.2.2.3 ONLINE PHARMACY 9.2.2.4 OTHERS

9.3 SURGICAL TREATMENT 9.4 THERAPY

9.4.1 ULTRAVIOLET LIGHT THERAPY 9.4.2 PHYSICAL THERAPY 9.4.3 OTHERS

10 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY END USER

10.1 OVERVIEW 10.2 HOSPITAL 10.3 SPECIALTY CLINICS 10.4 HOMECARE SETTINGS 10.5 OTHERS

11 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY GEOGRAPHY

11.1 EUROPE

11.1.1 U.K. 11.1.2 GERMANY 11.1.3 FRANCE 11.1.4 SPAIN 11.1.5 ITALY 11.1.6 NETHERLANDS 11.1.7 SWITZERLAND 11.1.8 BELGIUM 11.1.9 TURKEY 11.1.10 RUSSIA 11.1.11 REST OF EUROPE

12 EUROPE SCLERODERMA THERAPEUTICS MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: EUROPE

13 COMPANY PROFILES

13.1 ASTRAZENECA

13.1.1 COMPANY SNAPSHOT 13.1.2 REVENUE ANALYSIS 13.1.3 GEOGRAPHICAL PRESENCE 13.1.4 PRODUCT PORTFOLIO (PIPELINE) 13.1.5 RECENT DEVELOPMENTS

13.2 F. HOFFMANN-LA ROCHE LTD

13.2.1 COMPANY SNAPSHOT 13.2.2 REVENEUE ANALYSIS 13.2.3 GEOGRAPHICAL PRESENCE 13.2.4 PRODUCT PORTFOLIO 13.2.5 RECENT DEVELOPMENTS

13.3 NOVARTIS AG

13.3.1 COMPANY SNAPSHOT 13.3.2 REVENEUE ANALYSIS 13.3.3 GEOGRAPHICAL PRESENCE 13.3.4 PRODUCT PORTFOLIO 13.3.5 RECENT DEVELOPMENTS

13.4 PFIZER INC.

13.4.1 COMPANY SNAPSHOT 13.4.2 REVENEUE ANALYSIS 13.4.3 GEOGRAPHICAL PRESENCE 13.4.4 PRODUCT PORTFOLIO 13.4.5 RECENT DEVELOPMENTS

13.5 ABBVIE INC.

13.5.1 COMPANY SNAPSHOT 13.5.2 REVENEUE ANALYSIS 13.5.3 GEOGRAPHICAL PRESENCE 13.5.4 PRODUCT PORTFOLIO 13.5.5 RECENT DEVELOPMENTS

13.6 ACTIVE BIOTECH AB.

13.6.1 COMPANY OVERVIEW 13.6.2 REVENUE ANALYSIS 13.6.3 PRODUCT PORTFOLIO 13.6.4 RECENT DEVELOPMENT

13.7 ALLERGAN

13.7.1 COMPANY SNAPSHOT 13.7.2 REVENEUE ANALYSIS 13.7.3 GEOGRAPHICAL PRESENCE 13.7.4 PRODUCT PORTFOLIO 13.7.5 RECENT DEVELOPMENTS

13.8 ARGENTIS PHARMACEUTICALS, LLC.

13.8.1 COMPANY OVERVIEW 13.8.2 PRODUCT PORTFOLIO 13.8.3 RECENT DEVELOPMENTS

13.9 BRISTOL-MYERS SQUIBB COMPANY

13.9.1 COMPANY OVERVIEW 13.9.2 REVENUE ANALYSIS 13.9.3 GEOGRAPHICAL PRESENCE 13.9.4 PRODUCTS PORTFOLIO 13.9.5 RECENT DEVELOPMENTS

13.10 DAVAL INTERNATIONAL LIMITED

13.10.1 COMPANY SNAPSHOT 13.10.2 GEOGRAPHICAL PRESENCE 13.10.3 PRODUCT PORTFOLIO 13.10.4 RECENT DEVELOPMENT

13.11 GLAXOSMITHKLINE PLC.

13.11.1 COMPANY OVERVIEW 13.11.2 REVENUE ANALYSIS 13.11.3 GEOGRAPHICAL PRESENCE 13.11.4 PRODUCTS PORTFOLIO (PIPELINE DEVELOPMENT) 13.11.5 RECENT DEVELOPMENT

13.12 JOHNSON & JOHNSON SERVICES, INC.

13.12.1 COMPANY OVERVIEW 13.12.2 REVENUE ANALYSIS 13.12.3 GEOGRAPHICAL PRESENCE 13.12.4 PRODUCT PORTFOLIO (PIPELINE) 13.12.5 RECENT DEVELOPMENTS

13.13 SANOFI

13.13.1 COMPANY SNAPSHOT 13.13.2 REVENEUE ANALYSIS 13.13.3 GEOGRAPHICAL PRESENCE 13.13.4 PRODUCT PORTFOLIO 13.13.5 RECENT DEVELOPMENT

13.14 VIDA THERAPEUTICS INC.

13.14.1 COMPANY OVERVIEW 13.14.2 PRODUCT PORTFOLIO 13.14.3 RECENT DEVELOPMENTS

14 QUESTIONNAIRE 15 RELATED REPORTS

 

LIST OF TABLES EUROPE SCLERODERMA THERAPEUTICS MARKET

TABLE 1 INSIGHTS ABOUT CLINICAL TRIAL PHASES OF VARIOUS DRUGS TABLE 2 INCIDENCE AND PREVALENCE IN PAST DECADE (REGION) TABLE 3 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 4 EUROPE SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION) TABLE 5 EUROPE SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 6 EUROPE LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION) TABLE 7 EUROPE LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 8 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 9 EUROPE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 10 EUROPE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 11 EUROPE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 12 EUROPE SURGICAL TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY REGION 2017-2026 (USD MILLION) TABLE 13 EUROPE THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 14 EUROPE THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 15 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 16 EUROPE HOSPITAL IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 17 EUROPE SPECIALTY CLINICS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 18 EUROPE HOMECARE SETTINGS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 19 EUROPE OTHERS IN SCLERODERMA THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 20 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION) TABLE 21 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 22 EUROPE LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 23 EUROPE SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 24 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 25 EUROPE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 26 EUROPE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 27 EUROPE THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 28 EUROPE SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 29 U.K. SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 30 U.K. LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 31 U.K. SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 32 U.K. SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 33 U.K. DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 34 U.K. DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 35 U.K. THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 36 U.K. SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 37 GERMANY SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 38 GERMANY LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 39 GERMANY SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 40 GERMANY SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 41 GERMANY DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 42 GERMANY DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 43 GERMANY THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 44 GERMANY SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 45 FRANCE SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 46 FRANCE LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 47 FRANCE SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 48 FRANCE SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 49 FRANCE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 50 FRANCE DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 51 FRANCE THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 52 FRANCE SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 53 SPAIN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 54 SPAIN LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 55 SPAIN SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 56 SPAIN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 57 SPAIN DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 58 SPAIN DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 59 SPAIN THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 60 SPAIN SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 61 ITALY SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 62 ITALY LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 63 ITALY SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 64 ITALY SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 65 ITALY DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 66 ITALY DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 67 ITALY THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 68 ITALY SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 69 NETHERLANDS SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 70 NETHERLANDS LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 71 NETHERLANDS SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 72 NETHERLANDS SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 73 NETHERLANDS DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 74 NETHERLANDS DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 75 NETHERLANDS THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 76 NETHERLANDS SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 77 SWITZERLAND SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 78 SWITZERLAND LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 79 SWITZERLAND SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 80 SWITZERLAND SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 81 SWITZERLAND DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 82 SWITZERLAND DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 83 SWITZERLAND THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 84 SWITZERLAND SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 85 BELGIUM SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 86 BELGIUM LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 87 BELGIUM SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 88 BELGIUM SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 89 BELGIUM DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 90 BELGIUM DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 91 BELGIUM THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 92 BELGIUM SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 93 TURKEY SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 94 TURKEY LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 95 TURKEY SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 96 TURKEY SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 97 TURKEY DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 98 TURKEY DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 99 TURKEY THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 100 TURKEY SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 101 RUSSIA SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 102 RUSSIA LOCALIZED SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 103 RUSSIA SYSTEMIC SCLERODERMA IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 104 RUSSIA SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 105 RUSSIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION) TABLE 106 RUSSIA DRUG TREATMENT IN SCLERODERMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 107 RUSSIA THERAPY IN SCLERODERMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 108 RUSSIA SCLERODERMA THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 109 REST OF EUROPE SCLERODERMA THERAPEUTICS MARKET, BY TYPE, 2017-2026 (USD MILLION)

 

LIST OF FIGURES EUROPE SCLERODERMA THERAPEUTICS MARKET

FIGURE 1 BELOW IS THE SCLERODERMA MAP DEFINING THE TYPES FIGURE 2 EUROPE SCLERODERMA THERAPEUTICS MARKET: SEGMENTATION FIGURE 3 EUROPE SCLERODERMA THERAPEUTICS MARKET: DATA TRIANGULATION FIGURE 4 EUROPE SCLERODERMA THERAPEUTICS MARKET: DROC ANALYSIS FIGURE 5 EUROPE SCLERODERMA THERAPEUTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS FIGURE 6 EUROPE SCLERODERMA THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS FIGURE 7 EUROPE SCLERODERMA THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS FIGURE 8 EUROPE SCLERODERMA THERAPEUTICS MARKET: DBMR MARKET POSITION GRID FIGURE 9 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE SCLERODERMA THERAPEUTICS MARKET FIGURE 10 EUROPE SCLERODERMA THERAPEUTICS MARKET: SEGMENTATION FIGURE 11 RISING CASES OF SCLERODERMA, INCREASING ACCESS TO MEDICAL INSURANCE IN THE U.S., INCREASING MERGER AND ACQUISITIONS IS EXPECTED TO DRIVE THE EUROPE SCLERODERMA THERAPEUTICS MARKET IN THE FORECAST PERIOD 2019 TO 2026 FIGURE 12 SYSTEMIC SCLERODERMA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE SCLERODERMA THERAPEUTICS MARKET IN 2019 & 2026 FIGURE 13 EUROPE SCLERODERMA THERAPEUTICS MARKET: BY TYPE , 2018 FIGURE 14 EUROPE SCLERODERMA THERAPEUTICS MARKET: BY TREATMENT TYPE , 2018 FIGURE 15 EUROPE SCLERODERMA THERAPEUTICS MARKET: BY END USER, 2018 FIGURE 16 EUROPE SCLERODERMA THERAPEUTICS MARKET: SNAPSHOT (2018) FIGURE 17 EUROPE SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018) FIGURE 18 EUROPE SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2019 & 2026) FIGURE 19 EUROPE SCLERODERMA THERAPEUTICS MARKET: BY COUNTRY (2018 & 2026) FIGURE 20 EUROPE SCLERODERMA THERAPEUTICS MARKET: BY TYPE (2019-2026) FIGURE 21 EUROPE SCLERODERMA THERAPEUTICS MARKET: COMPANY SHARE 2018 (%)

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $3200.00
  • $2500.00
BUY NOW ADD TO CART